A Maryland truck driver suffered an “eye stroke” that left him blind, first in one eye and then the other.
A Louisiana woman vomited for weeks before being diagnosed with a brain dysfunction typically caused by a vitamin deficiency.
An Oklahoma real estate agent heard her colon pop as it ruptured while she drove her granddaughter home from a softball game. “My colon blew up. Literally blew up,” she said.
All three have filed lawsuits that blame the popular class of weight-loss drugs known as GLP-1 receptor agonists, which include Ozempic, Wegovy and Mounjaro, and they’re part of a growing number of lawsuits alleging the drugs’ makers failed to sufficiently warn of the risk of certain severe injuries.
The suits come as the use of the blockbuster drugs has skyrocketed, embraced by millions of Americans to manage diabetes, lower the risk of heart disease and lose weight. The drugs, which mimic a hormone that slows digestion, triggers insulin and helps people feel full longer, cut America’s stubbornly high obesity rates – for the first time in more than a decade – and show promise in aiding a range of conditions from kidney disease to drug addiction.
Special Interest Glance
When we talk about our inability to pay attention, to concentrate, we often mean and blame our phones. It’s easy, it’s meant to be easy. One flick of our index finger transports us from disaster to disaster, from crisis to crisis, from maddening lie to maddening lie.
In an apparent attempt to win back Donald Trump’s favour, Venezuelan opposition leader María Corina Machado told reporters she had “presented” her gold Nobel peace prize medal to the US president during a private meeting at the White House on Thursday.
Ask anybody about the Jewish vote for New York City Mayor Zohran Mamdani in the election, and they’ll tell you he lost it badly. If they saw the news coverage, the headlines put a number on it: One-third went to Mamdani, and two-thirds went to his opponent Andrew Cuomo. To backers of Israel, the support for Mamdani was too high. To others, it was read as a sign that Mamdani was too divisive for the Democratic Party coalition—alienating large segments of New York City’s Jewish electorate.





























